Prospective Monocentric Clinical-biological Database

Pancreatic adenocarcinoma (PA) is a solid cancer with a very poor prognosis with overall survival, all stages combined, not exceeding 5% at 5 years. The incidence and number of deaths caused by this type of tumor have been steadily increasing for two decades. In the absence of therapeutic advances, PA will be one of the leading causes of cancer deaths in 2030. In recent years, researchers and clinicians have now attempted to characterize and understand PA as a whole, through the various stages of its carcinogenesis and the analysis of its microenvironment. Indeed, the stroma of PA can represe

Trial Details

NCT ID
NCT04136132
Phase
NA
Sponsor
Institut du Cancer de Montpellier - Val d'Aurelle
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • Biological collection
Locations (sample)
  • Montpellier, Occ, France|43.61093,3.87635

Key Eligibility Criteria

  • Patient over the age of 18;
  • Patient managed for pancreatic adenocarcinoma;
  • Patient eligible for at least one (or more) surgery (s) and chemotherapy;
  • Patient giving informed consent

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →